NIOX Group Final Earnings Report

NIOX Group EPS Results

• Actual EPS: GBX 2.27
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NIOX Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NIOX Group Announcement Details

• Quarter: Final
• Date: 4/1/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

NIOX Group (LON:NIOX) is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries. NIOX is committed to enabling more precise and personalised care for patients with respiratory conditions, with a focus on quality, innovation, and scientific excellence.